Lantheus Holdings, parent company to Lantheus Medical Imaging, a global leader in developing, manufacturing, selling and distributing innovative diagnostic imaging agents, announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed initial public offering of its common stock. Lantheus Holdings intends to apply to list its common stock on the NASDAQ Global under the ticker symbol "LNTH." The number of shares to be offered and the price range of the proposed offering have not yet been determined. Lantheus Holdings expects to use the net proceeds of the offering to repay indebtedness of LMI and for working capital and general corporate purposes.

An investigational amyloid antibody treatment called solanezumab is being evaluated by Northwestern University School of Medicine and Rush University Medical Center in Chicago for its efficacy in slowing memory loss caused by Alzheimer's disease.

Using a multiparametric approach, PET/MR imaging with F-18 FDG, dynamic contrast-enhanced MRI, diffusion-weighted imaging and 3-D proton MR spectroscopic imaging is superior for telling apart different kinds of breast tumors, according to a study published online June 24 in Clinical Cancer Research.

ImaginAb announced earlier this month that IBA Molecular will be taking on radiochemistry, manufacturing and distribution of the diagnostic immunoPET agent for prostate cancer, Zr-89 Df-IAB2M, as U.S. clinical trials roll out.

There have been major cuts in 2014 physician fee schedules as compared to 2013.  Imaging centers are feeling top line reimbursement pressure which has directly impacted EBITDA growth over the past few years.  In response to negative growth in reimbursement rates and margins, centers will adapt to change what they have power over, namely expenses.  In this article, we will benchmark 30 freestanding, single site, multi-modality imaging centers for which VMG has had the privilege to provide valuation services. 

Regenerative medicine is generating growing interest in terms of research and market investment, according to a data analysis announced June 18 by Frost & Sullivan.

REM behavior disorder (RBD) is highly correlated with the development and progression of neurodegenerative disease including Parkinson’s, according to a brain study presented during the recent Society of Nuclear Medicine and Molecular Imaging’s 2014 Annual Meeting.

Jigsaw preclinical imaging is not a new concept. However novel instrumentation called Opti-SPECT/PET/CT presented during the 2014 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) held June 7-11 in St. Louis brings together a full spectrum of molecular imaging technology into one system—and one scan. Bioluminescence and fluorescence imaging agents developed with the platform could one day be implemented as intraoperative tracers during surgery, most notably for oncologic procedures.